{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:06:21Z","timestamp":1793815581488,"version":"4.6.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["RVO VFN 64165"],"award-info":[{"award-number":["RVO VFN 64165"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["AZV NV19-03-00007"],"award-info":[{"award-number":["AZV NV19-03-00007"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019214","name":"l\u00e9ka\u0159sk\u00e1 fakulta Univerzity Karlovy","doi-asserted-by":"publisher","award":["UNCE204065"],"award-info":[{"award-number":["UNCE204065"]}],"id":[{"id":"10.13039\/100019214","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019214","name":"l\u00e9ka\u0159sk\u00e1 fakulta Univerzity Karlovy","doi-asserted-by":"publisher","award":["SVV260631"],"award-info":[{"award-number":["SVV260631"]}],"id":[{"id":"10.13039\/100019214","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["EF16_013\/0001674"],"award-info":[{"award-number":["EF16_013\/0001674"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BBMRI_CZ","award":["LM2023033"],"award-info":[{"award-number":["LM2023033"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00428-023-03640-4","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T07:01:46Z","timestamp":1694070106000},"page":"497-507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma"],"prefix":"10.1007","volume":"483","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5869-3618","authenticated-orcid":false,"given":"Michaela","family":"Kendall B\u00e1rt\u016f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krist\u00fdna","family":"N\u011bmejcov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"Mich\u00e1lkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Stru\u017einsk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"H\u00e1jkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hojn\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Krkavcov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Laco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radoslav","family":"Mat\u011bj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Drozenov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"M\u00e9hes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Fabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitka","family":"Hausnerov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00e1n","family":"\u0160vajdler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"\u0160kapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cibula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Zima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Dundr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"3640_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2022.06.012","volume":"173","author":"K Almstedt","year":"2022","unstructured":"Almstedt K, Heimes AS, Kappenberg F, Battista MJ, Lehr HA, Krajnak S, Lebrecht A, Gehrmann M, Stewen K, Brenner W, Weikel W, Rahnenfuhrer J, Hengstler JG, Hasenburg A, Schmidt M (2022) Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. Eur J Cancer 173:10\u201319. https:\/\/doi.org\/10.1016\/j.ejca.2022.06.012","journal-title":"Eur J Cancer"},{"issue":"3","key":"3640_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/healthcare7030094","volume":"7","author":"T Amano","year":"2019","unstructured":"Amano T, Chano T, Yoshino F, Kimura F, Murakami T (2019) Current position of the molecular therapeutic targets for ovarian clear cell carcinoma: a literature review. Healthcare (Basel) 7(3):94. https:\/\/doi.org\/10.3390\/healthcare7030094","journal-title":"Healthcare (Basel)"},{"key":"3640_CR3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, To GATI (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687\u2013697. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X","journal-title":"Lancet"},{"key":"3640_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","volume":"35","author":"AN Bartley","year":"2017","unstructured":"Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA (2017) HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35:446\u2013464. https:\/\/doi.org\/10.1200\/JCO.2016.69.4836","journal-title":"J Clin Oncol"},{"key":"3640_CR5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3817","author":"KL Bolton","year":"2022","unstructured":"Bolton KL, Chen D, Corona de la Fuente RI, Fu Z, Murali R, Kobel M, Tazi Y, Cunningham JM, Chan ICC, Wiley BJ, Moukarzel LA, Winham SJ, Armasu SM, Lester J, Elishaev E, Laslavic A, Kennedy CJ, Piskorz A, Sekowska M, Brand AH, Chiew YE, Pharoah P, Elias KM, Drapkin R, Churchman M, Gourley C, DeFazio A, Karlan B, Brenton JD, Weigelt B, Anglesio MS, Huntsman D, Gayther SA, Konner J, Modugno F, Lawrenson K, Goode EL, Papaemmanuil E (2022) Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3817","journal-title":"Clin Cancer Res"},{"key":"3640_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","volume":"21","author":"MA Bookman","year":"2003","unstructured":"Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21:283\u2013290. https:\/\/doi.org\/10.1200\/JCO.2003.10.104","journal-title":"J Clin Oncol"},{"key":"3640_CR7","doi-asserted-by":"publisher","first-page":"100040","DOI":"10.1016\/j.modpat.2022.100040","volume":"36","author":"P Dundr","year":"2023","unstructured":"Dundr P, B\u00e1rt\u016f M, Bosse T, Bui QH, Cibula D, Drozenov\u00e1 J, Fabian P, Fadare O, Hausnerov\u00e1 J, Hojn\u00fd J, H\u00e1jkov\u00e1 N, Jak\u0161a R, Laco J, Lax SF, Mat\u011bj R, M\u00e9hes G, Mich\u00e1lkov\u00e1 R, \u0160afanda A, N\u011bmejcov\u00e1 K, Singh N, Stolnicu S, \u0160vajdler M, Zima T, Stru\u017einsk\u00e1 I, McCluggage WG (2023) Primary mucinous tumors of the ovary: an interobserver reproducibility and detailed molecular study reveals significant overlap between diagnostic categories. Mod Pathol 36:100040. https:\/\/doi.org\/10.1016\/j.modpat.2022.100040","journal-title":"Mod Pathol"},{"key":"3640_CR8","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","volume":"22","author":"Early Breast Cancer Trialists' Collaborative g","year":"2021","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative g (2021) Trastuzumab for early-stage, HER2-positive breast cancer a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol 22:1139\u20131150. https:\/\/doi.org\/10.1016\/S1470-2045(21)00288-6","journal-title":"Lancet Oncol"},{"issue":"5","key":"3640_CR9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3390\/cancers13051015","volume":"13","author":"D Eiger","year":"2021","unstructured":"Eiger D, Agostinetto E, Sa\u00fade-Conde R, de Azambuja E (2021) The exciting new field of HER2-low breast cancer treatment. Cancers (Basel) 13(5):1015. https:\/\/doi.org\/10.3390\/cancers13051015","journal-title":"Cancers (Basel)"},{"key":"3640_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.path.2019.01.009","volume":"12","author":"O Fadare","year":"2019","unstructured":"Fadare O, Parkash V (2019) Pathology of endometrioid and clear cell carcinoma of the ovary. Surg Pathol Clin 12:529\u2013564. https:\/\/doi.org\/10.1016\/j.path.2019.01.009","journal-title":"Surg Pathol Clin"},{"key":"3640_CR11","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","volume":"26","author":"AN Fader","year":"2020","unstructured":"Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O\u2019Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD (2020) Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res 26:3928\u20133935. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0953","journal-title":"Clin Cancer Res"},{"key":"3640_CR12","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","volume":"36","author":"AN Fader","year":"2018","unstructured":"Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O\u2019Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD (2018) Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2neu. J Clin Oncol 36:2044\u20132051. https:\/\/doi.org\/10.1200\/JCO.2017.76.5966","journal-title":"J Clin Oncol"},{"key":"3640_CR13","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/j.1349-7006.2002.tb01231.x","volume":"93","author":"M Fujimura","year":"2002","unstructured":"Fujimura M, Katsumata N, Tsuda H, Uchi N, Miyazaki S, Hidaka T, Sakai M, Saito S (2002) HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. Jpn J Cancer Res 93:1250\u20131257. https:\/\/doi.org\/10.1111\/j.1349-7006.2002.tb01231.x","journal-title":"Jpn J Cancer Res"},{"key":"3640_CR14","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2217\/fon.15.45","volume":"11","author":"I Gounaris","year":"2015","unstructured":"Gounaris I, Brenton JD (2015) Molecular pathogenesis of ovarian clear cell carcinoma. Future Oncol 11:1389\u20131405. https:\/\/doi.org\/10.2217\/fon.15.45","journal-title":"Future Oncol"},{"key":"3640_CR15","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3892\/or.2011.1456","volume":"26","author":"S Haruta","year":"2011","unstructured":"Haruta S, Furukawa N, Yoshizawa Y, Tsunemi T, Nagai A, Kawaguchi R, Tanase Y, Yoshida S, Kobayashi H (2011) Molecular genetics and epidemiology of epithelial ovarian cancer (review). Oncol Rep 26:1347\u20131356. https:\/\/doi.org\/10.3892\/or.2011.1456","journal-title":"Oncol Rep"},{"key":"3640_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/cncr.11476","volume":"98","author":"EV Hogdall","year":"2003","unstructured":"Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Norgaard-Pedersen B, Hogdall CK (2003) Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 98:66\u201373. https:\/\/doi.org\/10.1002\/cncr.11476","journal-title":"Cancer"},{"key":"3640_CR17","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/j.1365-2354.2009.01112.x","volume":"19","author":"M Hoopmann","year":"2010","unstructured":"Hoopmann M, Sachse K, Valter MM, Becker M, Neumann R, Ortmann M, Gohring UJ, Thomas A, Mallmann P, Schondorf T (2010) Serological and immunohistochemical HER-2\/neu statuses do not correlate and lack prognostic value for ovarian cancer patients. Eur J Cancer Care (Engl) 19:809\u2013815. https:\/\/doi.org\/10.1111\/j.1365-2354.2009.01112.x","journal-title":"Eur J Cancer Care (Engl)"},{"key":"3640_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature25475","volume":"554","author":"DM Hyman","year":"2018","unstructured":"Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189\u2013194. https:\/\/doi.org\/10.1038\/nature25475","journal-title":"Nature"},{"key":"3640_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","volume":"17","author":"A Chan","year":"2016","unstructured":"Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SKL, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J 2nd, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M, Exte NETSG (2016) Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 17:367\u2013377. https:\/\/doi.org\/10.1016\/S1470-2045(15)00551-3","journal-title":"Lancet Oncol"},{"key":"3640_CR20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/2159-8290.CD-17-0321","volume":"8","author":"MT Chang","year":"2018","unstructured":"Chang MT, Bhattarai TS, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, Chakravarty D, Phillips S, Kandoth C, Penson A, Gorelick A, Shamu T, Patel S, Harris C, Gao J, Sumer SO, Kundra R, Razavi P, Li BT, Reales DN, Socci ND, Jayakumaran G, Zehir A, Benayed R, Arcila ME, Chandarlapaty S, Ladanyi M, Schultz N, Baselga J, Berger MF, Rosen N, Solit DB, Hyman DM, Taylor BS (2018) Accelerating discovery of functional mutant alleles in cancer. Cancer Discov 8:174\u2013183. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0321","journal-title":"Cancer Discov"},{"issue":"2","key":"3640_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/diseases10020023","volume":"10","author":"J Chuang","year":"2022","unstructured":"Chuang J, Klempner S, Waters K, Atkins K, Chao J, Cho M, Hendifar A, Gangi A, Burch M, Mehta P, Gong J (2022) Therapeutic advances and challenges in the management of HER2-positive gastroesophageal cancers. Diseases 10(2):23. https:\/\/doi.org\/10.3390\/diseases10020023","journal-title":"Diseases"},{"key":"3640_CR22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1349-7006.2008.00747.x","volume":"99","author":"H Itamochi","year":"2008","unstructured":"Itamochi H, Kigawa J, Terakawa N (2008) Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 99:653\u2013658. https:\/\/doi.org\/10.1111\/j.1349-7006.2008.00747.x","journal-title":"Cancer Sci"},{"key":"3640_CR23","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/bjc.2017.228","volume":"117","author":"H Itamochi","year":"2017","unstructured":"Itamochi H, Oishi T, Oumi N, Takeuchi S, Yoshihara K, Mikami M, Yaegashi N, Terao Y, Takehara K, Ushijima K, Watari H, Aoki D, Kimura T, Nakamura T, Yokoyama Y, Kigawa J, Sugiyama T (2017) Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma. Br J Cancer 117:717\u2013724. https:\/\/doi.org\/10.1038\/bjc.2017.228","journal-title":"Br J Cancer"},{"key":"3640_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1046\/j.1525-1438.2003.13028.x","volume":"13","author":"H Iwamoto","year":"2003","unstructured":"Iwamoto H, Fukasawa H, Honda T, Hirata S, Hoshi K (2003) HER-2\/neu expression in ovarian clear cell carcinomas. Int J Gynecol Cancer 13:28\u201331. https:\/\/doi.org\/10.1046\/j.1525-1438.2003.13028.x","journal-title":"Int J Gynecol Cancer"},{"key":"3640_CR25","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1158\/2159-8290.CD-14-1211","volume":"5","author":"SM Kavuri","year":"2015","unstructured":"Kavuri SM, Jain N, Galimi F, Cottino F, Leto SM, Migliardi G, Searleman AC, Shen W, Monsey J, Trusolino L, Jacobs SA, Bertotti A, Bose R (2015) HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov 5:832\u2013841. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-1211","journal-title":"Cancer Discov"},{"key":"3640_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/PGP.0b013e3181c042b6","volume":"29","author":"M Kobel","year":"2010","unstructured":"Kobel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB, Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency VBC (2010) Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 29:203\u2013211. https:\/\/doi.org\/10.1097\/PGP.0b013e3181c042b6","journal-title":"Int J Gynecol Pathol"},{"key":"3640_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1309\/AJCPCX69HGDDGYCQ","volume":"143","author":"T Koopman","year":"2015","unstructured":"Koopman T, Louwen M, Hage M, Smits MM, Imholz AL (2015) Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma. Am J Clin Pathol 143:257\u2013264. https:\/\/doi.org\/10.1309\/AJCPCX69HGDDGYCQ","journal-title":"Am J Clin Pathol"},{"key":"3640_CR28","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s00432-014-1900-3","volume":"141","author":"T Koopman","year":"2015","unstructured":"Koopman T, Smits MM, Louwen M, Hage M, Boot H, Imholz AL (2015) HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison. J Cancer Res Clin Oncol 141:1343\u20131351. https:\/\/doi.org\/10.1007\/s00432-014-1900-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"3640_CR29","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/his.13704","volume":"73","author":"T Koopman","year":"2018","unstructured":"Koopman T, van der Vegt B, Dijkstra M, Bart J, Duiker E, Wisman GBA, de Bock GH, Hollema H (2018) HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation. Histopathology 73:852\u2013863. https:\/\/doi.org\/10.1111\/his.13704","journal-title":"Histopathology"},{"key":"3640_CR30","doi-asserted-by":"publisher","first-page":"e49829","DOI":"10.1371\/journal.pone.0049829","volume":"7","author":"E Lanitis","year":"2012","unstructured":"Lanitis E, Dangaj D, Hagemann IS, Song DG, Best A, Sandaltzopoulos R, Coukos G, Powell DJ Jr (2012) Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS One 7:e49829. https:\/\/doi.org\/10.1371\/journal.pone.0049829","journal-title":"PLoS One"},{"key":"3640_CR31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/01.pgp.0000152026.39268.57","volume":"24","author":"CH Lee","year":"2005","unstructured":"Lee CH, Huntsman DG, Cheang MC, Parker RL, Brown L, Hoskins P, Miller D, Gilks CB (2005) Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol 24:147\u2013152. https:\/\/doi.org\/10.1097\/01.pgp.0000152026.39268.57","journal-title":"Int J Gynecol Pathol"},{"key":"3640_CR32","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazieres J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Perol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Janne PA, Investigators DE-LT (2022) Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 386:241\u2013251. https:\/\/doi.org\/10.1056\/NEJMoa2112431","journal-title":"N Engl J Med"},{"key":"3640_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13048-017-0304-9","volume":"10","author":"M Li","year":"2017","unstructured":"Li M, Li H, Liu F, Bi R, Tu X, Chen L, Ye S, Cheng X (2017) Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy. J Ovarian Res 10:9. https:\/\/doi.org\/10.1186\/s13048-017-0304-9","journal-title":"J Ovarian Res"},{"key":"3640_CR34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ygyno.2016.11.045","volume":"144","author":"Y Maru","year":"2017","unstructured":"Maru Y, Tanaka N, Ohira M, Itami M, Hippo Y, Nagase H (2017) Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis. Gynecol Oncol 144:377\u2013383. https:\/\/doi.org\/10.1016\/j.ygyno.2016.11.045","journal-title":"Gynecol Oncol"},{"key":"3640_CR35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41523-022-00434-w","volume":"8","author":"F Miglietta","year":"2022","unstructured":"Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M, Cacciatore M, Genovesi E, De Bartolo D, Vernaci G, Amato O, Porra F, Conte P, Guarneri V, Dieci MV (2022) HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment. NPJ Breast Cancer 8:66. https:\/\/doi.org\/10.1038\/s41523-022-00434-w","journal-title":"NPJ Breast Cancer"},{"key":"3640_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA, Investigators DE-BT (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"3640_CR37","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1200\/JCO.19.02318","volume":"38","author":"S Modi","year":"2020","unstructured":"Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S (2020) Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol 38:1887\u20131896. https:\/\/doi.org\/10.1200\/JCO.19.02318","journal-title":"J Clin Oncol"},{"key":"3640_CR38","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I, Investigators DE-B (2020) Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382:610\u2013621. https:\/\/doi.org\/10.1056\/NEJMoa1914510","journal-title":"N Engl J Med"},{"key":"3640_CR39","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ccell.2018.09.010","volume":"34","author":"KB Pahuja","year":"2018","unstructured":"Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S (2018) Actionable activating oncogenic ERBB2\/HER2 transmembrane and juxtamembrane domain mutations. Cancer Cell 34:792-806 e795. https:\/\/doi.org\/10.1016\/j.ccell.2018.09.010","journal-title":"Cancer Cell"},{"key":"3640_CR40","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant Trial Study T (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672. https:\/\/doi.org\/10.1056\/NEJMoa052306","journal-title":"N Engl J Med"},{"key":"3640_CR41","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684. https:\/\/doi.org\/10.1056\/NEJMoa052122","journal-title":"N Engl J Med"},{"key":"3640_CR42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/ajcp\/111.3.311","volume":"111","author":"JS Ross","year":"1999","unstructured":"Ross JS, Yang F, Kallakury BV, Sheehan CE, Ambros RA, Muraca PJ (1999) HER-2\/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Am J Clin Pathol 111:311\u2013316. https:\/\/doi.org\/10.1093\/ajcp\/111.3.311","journal-title":"Am J Clin Pathol"},{"key":"3640_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/gcc.22507","volume":"57","author":"Y Shibuya","year":"2018","unstructured":"Shibuya Y, Tokunaga H, Saito S, Shimokawa K, Katsuoka F, Bin L, Kojima K, Nagasaki M, Yamamoto M, Yaegashi N, Yasuda J (2018) Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing. Genes Chromosomes Cancer 57:51\u201360. https:\/\/doi.org\/10.1002\/gcc.22507","journal-title":"Genes Chromosomes Cancer"},{"key":"3640_CR44","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792. https:\/\/doi.org\/10.1056\/NEJM200103153441101","journal-title":"N Engl J Med"},{"key":"3640_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","volume":"369","author":"I Smith","year":"2007","unstructured":"Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ, team Hs (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(07)60028-2","journal-title":"Lancet"},{"key":"3640_CR46","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","volume":"88","author":"T Sugiyama","year":"2000","unstructured":"Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88:2584\u20132589","journal-title":"Cancer"},{"key":"3640_CR47","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1200\/JCO.2016.66.9010","volume":"34","author":"T Sugiyama","year":"2016","unstructured":"Sugiyama T, Okamoto A, Enomoto T, Hamano T, Aotani E, Terao Y, Suzuki N, Mikami M, Yaegashi N, Kato K, Yoshikawa H, Yokoyama Y, Tanabe H, Nishino K, Nomura H, Kim JW, Kim BG, Pignata S, Alexandre J, Green J, Isonishi S, Terauchi F, Fujiwara K, Aoki D (2016) Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017\/GCIG trial. J Clin Oncol 34:2881\u20132887. https:\/\/doi.org\/10.1200\/JCO.2016.66.9010","journal-title":"J Clin Oncol"},{"key":"3640_CR48","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pathol.2022.11.004","volume":"55","author":"KL Talia","year":"2023","unstructured":"Talia KL, Banet N, Buza N (2023) The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma. Pathology 55:8\u201318. https:\/\/doi.org\/10.1016\/j.pathol.2022.11.004","journal-title":"Pathology"},{"key":"3640_CR49","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1158\/1078-0432.CCR-10-1688","volume":"17","author":"DS Tan","year":"2011","unstructured":"Tan DS, Iravani M, McCluggage WG, Lambros MB, Milanezi F, Mackay A, Gourley C, Geyer FC, Vatcheva R, Millar J, Thomas K, Natrajan R, Savage K, Fenwick K, Williams A, Jameson C, El-Bahrawy M, Gore ME, Gabra H, Kaye SB, Ashworth A, Reis-Filho JS (2011) Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res 17:1521\u20131534. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1688","journal-title":"Clin Cancer Res"},{"key":"3640_CR50","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ygyno.2004.05.055","volume":"94","author":"H Tanabe","year":"2004","unstructured":"Tanabe H, Nishii H, Sakata A, Suzuki K, Mori Y, Shinozaki H, Watanabe A, Ochiai K, Yasuda M, Tanaka T (2004) Overexpression of HER-2\/neu is not a risk factor in ovarian clear cell adenocarcinoma. Gynecol Oncol 94:735\u2013739. https:\/\/doi.org\/10.1016\/j.ygyno.2004.05.055","journal-title":"Gynecol Oncol"},{"key":"3640_CR51","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","volume":"142","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med 142:1364\u20131382. https:\/\/doi.org\/10.5858\/arpa.2018-0902-SA","journal-title":"Arch Pathol Lab Med"},{"key":"3640_CR52","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ygyno.2004.08.043","volume":"95","author":"Y Wu","year":"2004","unstructured":"Wu Y, Soslow RA, Marshall DS, Leitao M, Chen B (2004) Her-2\/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol Oncol 95:570\u2013575. https:\/\/doi.org\/10.1016\/j.ygyno.2004.08.043","journal-title":"Gynecol Oncol"},{"key":"3640_CR53","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.3802\/jgo.2017.28.e32","volume":"28","author":"W Yamagami","year":"2017","unstructured":"Yamagami W, Nagase S, Takahashi F, Ino K, Hachisuga T, Aoki D, Katabuchi H (2017) Clinical statistics of gynecologic cancers in Japan. J Gynecol Oncol 28:e32. https:\/\/doi.org\/10.3802\/jgo.2017.28.e32","journal-title":"J Gynecol Oncol"},{"key":"3640_CR54","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.3802\/jgo.2019.30.e85","volume":"30","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, Yoshikawa N, Shirakawa A, Niimi K, Suzuki S, Kajiyama H, Kikkawa F (2019) Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma. J Gynecol Oncol 30:e85. https:\/\/doi.org\/10.3802\/jgo.2019.30.e85","journal-title":"J Gynecol Oncol"},{"key":"3640_CR55","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/IGC.0b013e3182788466","volume":"23","author":"D Zhao","year":"2013","unstructured":"Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J (2013) Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 23:25\u201333. https:\/\/doi.org\/10.1097\/IGC.0b013e3182788466","journal-title":"Int J Gynecol Cancer"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-023-03640-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-023-03640-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-023-03640-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T08:03:27Z","timestamp":1698480207000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-023-03640-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["3640"],"URL":"https:\/\/doi.org\/10.1007\/s00428-023-03640-4","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"assertion":[{"value":"5 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the Ethics Committee of the General University Hospital in Prague in compliance with the Helsinki Declaration. The Ethics Committee did not require the procurement of informed consent, given that according to the Czech Law (Act. no. 373\/11, and its amendment Act no. 202\/17) it is not necessary to provide informed consent in fully anonymized studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}